Safety and efficacy of dronedarone in blanking period in patients underwent atrial fibrillation catheter ablation
AIM To evaluate the safety and efficacy of dronedarone in the blanking period in patients underwent atrial fibrillation catheter ablation in the real-world.METHODS A total of 150 patients with atrial fibrillation who underwent catheter ablation at co-operative centers between May 1st,2021 and December 31st,2021 were included.During the blanking period,the patients were given oral dronedarone(400 mg,morning and evening)for 3 months.At 3 months±14 days after surgery,the patients were followed up,and 24-hour Holter,transthoracic echocardiography,liver function and renal function were reviewed.The adverse events occurred during the follow-up were recorded.RESULTS Compared with before surgery,there were no significant differences in heart rate,PR interval,and left ventricular ejection fraction were observed at 3 months after surgery,while QTc interval increased((434.0±29.2)ms vs.(443.5±31.8)ms,P=0.017)).Left atrial diameter((40.6±6.5)mm vs.(38.4±6.0)mm,P=0.007))and lower left ventricular end-diastolic diameter((47.9±4.3)mm vs.(46.4±5.1)mm,P=0.012))decreased.Six patients discontinued in the blanking period(included high atrioventricular block in 1 patient,significant bradycardia in 2 patients,significant prolongation of the QTc interval in 1 patient,and digestive system symptoms in 2 patients).There were no composite endpoints of cardiovascular death,heart failure or rehospitalization associated with antiarrhythmic drugs.At follow-up of 3 months,the rate of sinus rhythm maintenance was 85.3％(128/150).CONCLUSION Dronedarone is safe and effective in the blanking period for patients underwent atrial fibrillation catheter ablation.Moreover,it's good in adherence.
dronedaroneatrial fibrillationradiofrequency ablationanti-arrhythmia agentsblanking period
NETL
NSTL
万方数据
